in their hematologic parameters and 30% of patients achieved a marrow CR (mCR), only half of those who achieved mCR recovered their blood counts.32Additionally, most people who responded to treatment did so by cycle two, which suggests that decitabine works more like low-dose chemotherapy rather...
Main side effects were tolerable hematologic toxicities. In conclusion, low-dose decitabine plus ATRA is a promising treatment for patients with myeloid neoplasms judged ineligible for intensive chemotherapy.doi:10.1007/s00277-016-2681-3Wu, Wei
in patients 65 years of age or older who are not candidates for standard induction chemotherapy. decitabine is given by intravenous infusion, diluted to a final concentration of 0. 1 to 1 mg/ml in sodium chloride 0.9%, glucose 5%, or lactated ringer's injection. for the treatment of ...
Note. Data isn(%). CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate. Tumors were assessed every 2 cycles...
It is appreciated that differentiation of cells with self-renewal potential increases the sensitivity chemotherapy37,38. This correlates with the observation that epigenetic therapies sensitize tumors to chemotherapy treatments10,39,40. DNA-demethylating agents also alter the immune response by reactivating...
MPN or MDS/MPN other categories; therefore, she was diagnosed with MDS/MPN-U accord ing to the World Health Organization's 2016 version of haematologic neoplasm classification.3 After diagnosis, the patient rejected chemotherapy con sidering its side effects and was only treated with sympto...
Cancer Chemotherapy and Pharmacology 61, 759–766, 10.1007/s00280-007-0531-7 (2008). Article CAS PubMed Google Scholar Chowdhury, B., Cho, I.-H., Hahn, N. & Irudayaraj, J. Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer ...
Compared with a historical group of 54 patients with MDS who received intensive chemotherapy (2000–2003) and matched for age, cytogenetics and IPSS/FAB, the CR rate was lower with decitabine (28% vs 47%), but the overall response rate was favorable; the 8-week mortality was also lower ...
S phase–specific drugs can be used at very high doses for a limited duration without unacceptable side effects. Patients with metastatic malignancy and poor prognosis are potentially good candidates for intense chemotherapy with 5-AZA-CdR. As an initial study, we suggest a dose schedule of 60 ...
MPN or MDS/MPN other categories; therefore, she was diagnosed with MDS/MPN-U accord ing to the World Health Organization's 2016 version of haematologic neoplasm classification.3 After diagnosis, the patient rejected chemotherapy con sidering its side effects and was only treated with sympto...